Research team Dan Grandér

Denna sida på svenska

Molecular mechanisms of action of anti-cancer drugs and role of non-coding RNA in cancer

The aim of our research is to improve conditions for the use of anti-cancer drugs in patients with cancer. The group runs two major projects: studies on the mechanisms of cell death (and resistance) induced by well-known as well as novel anti-cancer drugs and the role of non-coding RNA in cancer.

Projects

Mechanisms of action of anti-cancer drugs
Long non-coding RNAs in tumor development
Transcription factor and oncogene STAT3 as a target for anti-cancer therapy
STAT1 and STAT3 - mechanisms of interaction and inhibition of signaling

Funding

  • Swedish Cancer Society (Mechanisms of action of anti-cancer drugs)
  • Swedish Research Council (Molecular mechanisms of cell death induced by anti-cancer drugs)
  • The Swedish Childhood Cancer Foundation (Drug-induced apoptosis in pediatric leukemia, mechanisms of action and resistance)
  • King Gustaf V Jubilee Fund (Genetic changes in malignant tumors)
  • The Cancer Society in Stockholm (Molecular mechanisms of cell death induced by anti-cancer agents)

Group members

Ann-Charlotte Björklund, Research Technician
Sander Busker, MSc, PhD student
Matheus Dyczynski, MSc, PhD student
Katja Pokrovskaja Tamm, PhD, Associate Professsor
Jason Tyler Serviss, MSc, PhD student
Linda Vidarsdottir, MSc, PhD student
Yasmin Yu, MSc, PhD student
Vasilios Zachariadis, MD, PhD, Postdoc
Martin Enge, PhD, Assistant Professor
 

Selected publications

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, Haraldsson M, et al
PLoS ONE 2017 ;12(6):e0178844

Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells.
Pellegrini P, Dyczynski M, Sbrana F, Karlgren M, Buoncervello M, Hägg-Olofsson M, et al
Oncotarget 2016 Jun;7(24):35703-35723

Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs.
Kolosenko I, Fryknäs M, Forsberg S, Johnsson P, Cheon H, Holvey-Bates E, et al
Int. J. Cancer 2015 Feb;136(4):E51-61

A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells.
Johnsson P, Ackley A, Vidarsdottir L, Lui W, Corcoran M, Grandér D, et al
Nat. Struct. Mol. Biol. 2013 Apr;20(4):440-6

Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway.
Arabi A, Ullah K, Branca R, Johansson J, Bandarra D, Haneklaus M, et al
Nat Commun 2012 ;3():976

MiR-200c regulates Noxa expression and sensitivity to proteasomal inhibitors.
Lerner M, Haneklaus M, Harada M, Grandér D
PLoS ONE 2012 ;7(5):e36490

Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia.
Harada M, Pokrovskaja-Tamm K, Söderhäll S, Heyman M, Grander D, Corcoran M
Leuk. Lymphoma 2012 Oct;53(10):2041-50

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.
Buentke E, Nordström A, Lin H, Björklund A, Laane E, Harada M, et al
Blood Cancer J 2011 Jul;1(7):e31

MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.
Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng H, Akbari Moqadam F, et al
Cell Cycle 2011 Jul;10(13):2172-83

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.
Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, et al
Exp. Cell Res. 2009 Oct;315(17):2941-52

Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy.
Laane E, Tamm K, Buentke E, Ito K, Kharaziha P, Khahariza P, et al
Cell Death Differ. 2009 Jul;16(7):1018-29

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.
Buentke E, Nordström A, Lin H, Björklund A, Laane E, Harada M, et al
Blood Cancer J 2011 Jul;1(7):e31

Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin.
Panaretakis T, Hjortsberg L, Tamm K, Björklund A, Joseph B, Grandér D
Mol. Biol. Cell 2008 Jan;19(1):41-50